Natera Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 5, 2026 results vs estimates
Natera Inc Forecast
Natera Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 37.9% a year, a typical one-standard-deviation range is 412.70–459.30 over a week, 388.24–483.76 over a month and 270.56–601.44 over a year. (Signals as of 1 Nov 2026.)
Natera Inc Price Chart
Natera Inc Factors
YoY +44.5%
YoY +33.0%
YoY +46.4%
YoY −71.8%
YoY −73.2%
YoY +98.5%
YoY +1.7%
YoY −14.2%
YoY −14.9%
YoY −68.4%
YoY −19.5%
YoY +20.0%
YoY +31.4%
Natera Inc fundamentals: income statement, balance sheet & cash flow
Natera Inc reported revenue of $2.31bn and net income of -$208.2m in FY2025, the year ended 31 December 2025 — revenue up 35.9% and net income down 9.3% on the prior year. Free cash flow was $109.1m. These figures are as reported in the filings, not restated: 14 fiscal years and 55 quarters of history, back to December 2012. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 2,306.1 | 1,696.9 | 1,082.6 | 820.2 | 625.5 |
| Cost of revenue | 810.6 | 673.8 | 589.8 | 456.3 | 318.4 |
| Gross profit | 1,495.5 | 1,023.2 | 492.7 | 364.0 | 307.1 |
| Research & development | 624.1 | 404.1 | 320.7 | 316.4 | 264.2 |
| Selling, general & admin. | 1,177.3 | 841.3 | 618.3 | 588.6 | 511.0 |
| Operating income | -309.9 | -222.3 | -446.2 | -541.0 | -468.2 |
| EBITDA | -220.5 | -148.1 | -397.8 | -520.8 | -451.5 |
| Interest expense | 4.1 | 10.7 | 12.6 | 9.3 | 8.3 |
| Pre-tax income | -268.1 | -189.7 | -434.5 | -546.8 | -471.1 |
| Income tax | -59.9 | 0.7 | 0.3 | 1.0 | 0.6 |
| Net income | -208.2 | -190.4 | -434.8 | -547.8 | -471.7 |
Download Natera Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.NTRA.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Natera Inc
Explore MacroFinance macro & markets research and analysis.
Natera Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Natera Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Natera Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Natera Inc (United States)
Natera Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Natera Inc?
What is the latest Natera Inc price?
Is Natera Inc in an uptrend?
How volatile is Natera Inc?
What factors affect Natera Inc?
Which trading strategies trade Natera Inc?
How are Natera Inc returns analysed?
Where can I download free Natera Inc historical data?
Free Natera Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Natera Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NTRA.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 273.4 |
| 2026-11-19 | 289.92 |
| 2026-11-18 | 289.5 |
| 2026-11-17 | 287.47 |
| 2026-11-16 | 288.48 |
| 2026-11-13 | 319.09 |
| 2026-11-12 | 322.94 |
| 2026-11-11 | 319.82 |
| 2026-11-10 | 311.98 |
| 2026-11-09 | 320.39 |
About this stock
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.